Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$832M |
| 2 |
Johnson & Johnson
JNJ
|
+$706M |
| 3 |
Datadog
DDOG
|
+$549M |
| 4 |
Amazon
AMZN
|
+$442M |
| 5 |
Eli Lilly
LLY
|
+$372M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Workday
WDAY
|
+$1.22B |
| 2 |
AbbVie
ABBV
|
+$1.07B |
| 3 |
Advanced Micro Devices
AMD
|
+$817M |
| 4 |
Amgen
AMGN
|
+$706M |
| 5 |
Honeywell
HON
|
+$659M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.69% |
| 2 | Healthcare | 17.58% |
| 3 | Consumer Discretionary | 10.69% |
| 4 | Financials | 10.23% |
| 5 | Communication Services | 9.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Ardelyx
ARDX
$1.25B
| $124M | 0.06% |
24,387,941
+2,858,061
| +13% | +$15.8M |
|
252
iShares Core S&P 500 ETF
IVV
$871B
| $123M | 0.06% |
+209,169
| New | +$124M |
|
253
Keysight
KEYS
$52.2B
| $122M | 0.06% |
761,527
-71,281
| -9% | -$11.5M |
|
254
EnerSys
ENS
$6.69B
| $122M | 0.06% |
1,322,767
+13,786
| +1% | +$1.34M |
|
255
Alight
ALIT
$523M
| $122M | 0.06% |
881,229
+11,474
| +1% | +$1.68M |
|
256
Gilead Sciences
GILD
$167B
| $120M | 0.06% |
1,296,077
-465,484
| -26% | -$41.9M |
|
|
ACLX
257
DELISTED
Arcellx
ACLX
| $119M | 0.06% |
1,557,092
-454,858
| -23% | -$39.3M |
|
258
UL Solutions
ULS
$18.5B
| $119M | 0.06% |
2,389,077
+81,426
| +4% | +$4.22M |
|
259
Williams Companies
WMB
$85.8B
| $119M | 0.06% |
2,194,402
-1,274,424
| -37% | -$68.7M |
|
260
Doximity
DOCS
$3.85B
| $114M | 0.06% |
2,142,478
-322,409
| -13% | -$15.8M |
|
261
BellRing Brands
BRBR
$1.59B
| $114M | 0.06% |
1,514,623
-260,936
| -15% | -$18.5M |
|
262
Structure Therapeutics
GPCR
$3.4B
| $113M | 0.06% |
4,159,888
+203,010
| +5% | +$7.2M |
|
263
Xenon Pharmaceuticals
XENE
$6.28B
| $112M | 0.06% |
2,866,755
+314,363
| +12% | +$13M |
|
264
Nice
NICE
$5.94B
| $110M | 0.06% |
650,056
+5,609
| +0.9% | +$1,000K |
|
265
Xylem
XYL
$29.2B
| $109M | 0.06% |
938,055
-301,495
| -24% | -$38.1M |
|
266
Ligand Pharmaceuticals
LGND
$5.94B
| $109M | 0.06% |
1,015,023
+5,929
| +0.6% | +$670K |
|
267
Neurocrine Biosciences
NBIX
$18.4B
| $108M | 0.06% |
794,118
+1,922
| +0.2% | +$238K |
|
268
Arista Networks
ANET
$214B
| $107M | 0.05% |
971,547
-456,709
| -32% | -$47M |
|
269
Sotera Health
SHC
$5.06B
| $106M | 0.05% |
7,782,562
-4,886,228
| -39% | -$70.8M |
|
270
SPX Corp
SPXC
$10.2B
| $105M | 0.05% |
723,708
+26,995
| +4% | +$4.35M |
|
271
Inspire Medical Systems
INSP
$1.5B
| $105M | 0.05% |
567,312
+64,703
| +13% | +$12.6M |
|
272
PTC Therapeutics
PTCT
$6.25B
| $105M | 0.05% |
2,325,915
+455,698
| +24% | +$19.5M |
|
273
Marathon Petroleum
MPC
$89.3B
| $103M | 0.05% |
737,907
-35,291
| -5% | -$5.39M |
|
274
Paylocity
PCTY
$7.43B
| $103M | 0.05% |
514,471
-3,460
| -0.7% | -$662K |
|
275
NeoGenomics
NEO
$1.74B
| $102M | 0.05% |
6,165,063
-438,117
| -7% | -$6.8M |
|
Similar funds
Janus Henderson Group's Q4 2024 Portfolio in Review
As of Q4 2024, Janus Henderson Group held 2,620 positions worth $197B, up 0.7% from $195B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Janus Henderson Group's Q4 2024 filing shows 92 new, 801 increased, 713 reduced and 96 closed positions. Its largest new stake was Lam Research: 10,967,975 shares worth $792M. The largest sale was Workday, an estimated $1.22B.
By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 34% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q4 2024 buy was Lam Research: 10,967,975 shares worth $792M.
- Janus Henderson Group added most to Johnson & Johnson in Q4 2024, an estimated $706M increase.
- Janus Henderson Group's biggest Q4 2024 reduction was Workday, cutting an estimated $1.22B.
- Janus Henderson Group fully exited Coca-Cola Europacific Partners in Q4 2024, selling an estimated $52.4M.
- Janus Henderson Group's ten largest holdings make up 32% of its $197B portfolio in Q4 2024.
- Janus Henderson Group opened 92 new positions and closed 96 in Q4 2024.
- Janus Henderson Group's portfolio value rose 0.7% quarter-over-quarter to $197B.
Based on Janus Henderson Group's 13F filing for Q4 2024, filed 14 Feb 2025.